Skip to content
DataLookout
Menu

RENEW-MDD-3NCT07928245

A Study of Brenipatide in Participants With Major Depressive Disorder

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below.

  1. Notable Recruitment opened
    • Study sites: 75 to 76
    • Start date changed from estimate of Nov 2026 to Nov 10, 2026
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS-9) Score
Timeframe: Baseline, Week 10

Secondary (4)

Change from Baseline in Hamilton Depression Rating Scale Score
Change from Baseline in Sheehan Disability Scale (SDS) Global Functional Impairment Score
Achievement of Body Weight Reduction ≥5% in Participants with a Baseline Body Mass Index (BMI) ≥25 kg/m²
Number of Participants with Treatment-Emergent Anti-Drug Antibodies (ADA)

Arms and interventions

BrenipatideExperimental

Brenipatide administered subcutaneously (SC) + standard of care (SoC) anti-depressant

PlaceboPlacebo comparator

Placebo administered SC + SoC anti-depressant

Drugs: Brenipatide, Placebo

Sites

76 sites in 8 countries

United States 35, Poland 10, Romania 8, Spain 7, Bulgaria 5, Netherlands 5, United Kingdom 4, Hungary 2